All In Biotech

Drug Trial Radar · NCT01806272

Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis

A Open,Randomized Phase II Trial Comparing Local Use of rhGM-CSF and Compound Vitamin B12 Solution to Compound Vitamin B12 Solution Alone Treating Chemoradiotherapy-induced Oral Mucositis in Patients With Primary Nasopharyngeal Carcinoma

Last checked: Nov 19, 2026Latest source record: Mar 29, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

160

Planned (sponsor's estimate)

Start

Mar 2013

Primary completion

Jun 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Wei LUOAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a open,randomized phase II trial comparing effectiveness and safety of local use of rhGM-CSF and Compound Vitamin B12 to Compound Vitamin B12 solution alone treating oral mucositis in primary nasopharyngeal cancer. The main end point is the incidence of grade II and less oral mucositis at the end of treatment.The hypothesis of the study is that the local use of rhGM-CSF and Compound Vitamin B12 can decrease the incidence of grade III and more oral mucositis at the end of treatment compared to local use of Compound Vitamin B12 alone.

Conditions

  • Nasopharyngeal Cancers

Interventions

  • rhGM-CSFDrug

    The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.

  • Compound Vitamin B12Drug

    Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of grade II and less oral mucositis at the end of treatmentTime frame: 7 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.